Published in:
Open Access
01-12-2008 | Research article
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
Authors:
Asma Sultana, Paula Ghaneh, David Cunningham, Naureen Starling, John P Neoptolemos, Catrin Tudur Smith
Published in:
BMC Cancer
|
Issue 1/2008
Login to get access
Abstract
Background
Recent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer. There is paucity of evidence in the form of direct head-to-head randomised controlled trials to determine which combinations are to be preferred.
Method
Using the adjusted indirect comparison method proposed by Bucher et al, we have assessed randomised controlled trials of four gemcitabine based combinations namely gemcitabine plus a platinum compound or 5-fluorouracil or irinotecan or capecitabine.
Results
No particular combination was significantly superior to another, but the indirect evidence suggests some important trends.
Conclusion
The strongest trends on indirect comparison are towards favouring gemcitabine plus capecitabine or gemcitabine plus a platinum compound over gemcitabine plus irinotecan, and to a lesser degree, over gemcitabine plus 5-fluorouracil.